Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a research note released on Friday.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Stock Up 2.0 %

Shares of AUPH stock opened at $8.49 on Friday. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.05. The stock has a market cap of $1.21 billion, a PE ratio of -57.26 and a beta of 1.45. The business’s fifty day moving average is $7.13 and its 200-day moving average is $6.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AUPH. SG Americas Securities LLC grew its holdings in shares of Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after buying an additional 535,301 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aurinia Pharmaceuticals during the third quarter valued at $3,330,000. Stonepine Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at $1,713,000. AQR Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at $1,155,000. Finally, Nordea Investment Management AB boosted its position in Aurinia Pharmaceuticals by 51.7% during the first quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock valued at $1,552,000 after purchasing an additional 105,100 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.